A prospective, interventional, multicenter, Phase IV, open-label, single arm study to assess the safety and effectiveness of finerenone in participants from India with chronic kidney disease associated with type 2 diabetes. - None

Bayer AG0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年8月21日

试验速览

阶段: 4 期
状态: 招募中
发起方: Bayer AG

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1) Participants capable of giving signed informed consent signed before any study specific procedure and willing to comply with the study-related procedures. If a participant is incapable of giving signed informed consent, legally authorized representative (LAR) of participant can also sign the ICF.
•2) Diagnosis of CKD associated with T2D.
•3) Participants who are drug naïve for finerenone or patients who have been initiated on finerenone therapy within 4 weeks before signing the informed consent.
•4) Participants with serum potassium level = 4.8 mmol/L at the time of Screening. If serum potassium level > 4.8 to 5.0 mmol/L, participants may be enrolled in the study, but additional potassium samples may be required; the potassium level needs to be confirmed during Screening. Participants with potassium level > 5.0 mmol/L are not allowed. The sample for potassium assessment for confirming eligibility shall be available before initiation of treatment with finerenone.
•5) Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
•a) Women of childbearing potential (WOCBP) can only be included in the study if a urine pregnancy test is negative at the Screening visit and if they agree to use adequate contraception during the study and until 8 weeks after the last dose of finerenone. Adequate contraception is defined as any combination of at least two effective methods of birth control, of which at least one is a physical barrier (e.g., condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices).
•b) Postmenopausal females (no menses for 12 months without an alternative medical cause; see Appendix 4) are not required to use contraception. A high follicle-stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement is required.
•c) Females on HRT and whose menopausal status is in doubt will be required to use one of the non-estrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
•d) Females of nonchildbearing potential (documented hysterectomy, documented bilateral salpingectomy, documented bilateral oophorectomy) are not required to use contraception.
•e) For females with permanent infertility due to an alternate medical cause other than the above (e.g., Mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry.

排除标准

•1) Contraindications according to the local marketing authorization:
•a) Participants with eGFR < 25 mL/min/1.73m2 (calculated based on the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation, using 2009 formula). eGFR can be reassessed once within 48 hours.
•b) Participants with severe hepatic impairment (Child-Pugh C).
•c) Participants with known hypersensitivity to the study treatment (active substance or excipients).
•d) Participants with Type 1 Diabetes
•e) Participants taking concomitant medications that are strong CYP3A4 inhibitors
•f) Participants with Addison’s disease.
•2) Glycated hemoglobin (HbA1c) > 12% (17.5 mmol/L) at the Screening visit.
•3) Participants treated with another mineralocorticoid receptor antagonist, a renin inhibitor, potassium supplements, a potassium sparing diuretic, a potassium binder agent, or angiotensin receptor neprilysin inhibitor (ARNI) within 8 weeks prior to the Screening visit and during finerenone treatment.
•4) Participation in another interventional clinical trial within 30 days prior to the Screening visit and during finerenone treatment.
•5) Female participants who are pregnant or breast-feeding or plan to become pregnant or to breastfeed during the course of the study.
•6) Participants known for lack of compliance with clinic visits or prescribed medication.

研究者

发起方

Bayer AG

相似试验

招募中

4 期

Post marketing study to validate the efficacy and safety of Pravek Rumakalp for the treatment of musculoskeletal pain.

CTRI/2023/10/059140Pravek Kalp (P) Limite

进行中（未招募）

1 期

Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB)

EUCTR2018-001009-98-DERHEACELL GmbH & Co. KG16

进行中（未招募）

1 期

Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB)Recessive dystrophic epidermolysis bullosa (RDEB)MedDRA version: 20.0Level: PTClassification code 10014989Term: Epidermolysis bullosaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders

EUCTR2018-001009-98-ITRHEACELL GmbH & Co. KG18

进行中（未招募）

1 期

EUCTR2018-001009-98-GBRHEACELL GmbH & Co. KG16

进行中（未招募）

1 期

EUCTR2018-001009-98-ATRHEACELL GmbH & Co. KG16